Aim The aim of this study was to investigate the metabolism and elimination of donepezil HCl in humans, following the administration of a single 5 mg (liquid) oral dose containing a mixture of unlabelled and 14 C-labelled donepezil. Methods This was an open-label, non-randomized study in healthy male volunteers (n=8). Characterization of donepezil metabolism and elimination was performed by analysing blood, urine and faecal samples collected over a 10-day period following drug administration. Each collected sample was assayed for total radioactivity, and aliquots from specified time-points and/or pooled samples were assayed for the presence of donepezil metabolites by thin-layer chromatography (TLC). Donepezil concentrations in plasma were determined by HPLC. Results Recovery of radioactivity in subject samples averaged 72% of the administered dose. Recovery of the administered dose in urine (57%) was significantly greater than that recovered in faeces (15%). Unchanged donepezil accounted for the largest component of the recovered dose in each matrix. Three metabolic pathways were identified: (i) O-dealkylation and hydroxylation to metabolites M1 and M2, with subsequent glucuronidation to metabolites M11 and M12; (ii) hydrolysis to metabolite M4; and (iii) N-oxidation to metabolite M6.
Introduction same studies found that faecal elimination of donepezil, accounting for 59.7% of the dose, predominated over renal Pre-clinical metabolism and elimination studies in rats and dogs have shown that donepezil HCl (also known as E2020 excretion (39.2% of dose). Human pharmacokinetic studies confirm that donepezil undergoes first-pass hepatic metabor AriceptA, the registered trademark of Eisai Co. Ltd, Tokyo, Japan) undergoes significant first-pass metabolism.
olism following oral administration, but in contrast to findings in animal studies, the primary route of elimination Following administration of a single oral dose of 14 Cdonepezil in dogs, 55% of the radioactivity is present in the in humans was renal [1, 2] . In vitro studies using human hepatic microsomes have blood as metabolites, predominantly the O-glucuronide identified the cytochrome P-450 isoenzyme CYP-3A4 as primarily responsible for the metabolism of donepezil, with CYP-2D6 playing a lesser role (AriceptA US package insert, 1998). Pharmacokinetic and clinical studies with Alzheimer's produced by substituting 14 C at position 2 in the indanone ring. Following drug administration, the subjects remained patients indicate that the clearance of donepezil from plasma is unaffected by age, and that dose modification is not in an upright position (>45°angle from supine) and continued to fast from food and fluids for a further 4 h. necessary in the elderly [1] . Other studies, reported in this supplement, indicate that donepezil does not interact Subjects remained as in-patients for 10 days following drug administration. Urine, faecal and blood samples were adversely with other hepatically metabolized drugs such as cimetidine, ketoconazole, digoxin, warfarin and theophylcollected at specified intervals throughout the 10-day period for the measurement of 14 C-labelled donepezil and for line, and that the kinetics of single doses of donepezil are not significantly changed in patients with impaired hepatic metabolic profiling. The subjects were discharged from the study site on the morning of day 11, following a final and renal function.
Although much pharmacokinetic and pharmacodynamic discharge evaluation. Throughout the study, subjects abstained from physical data on donepezil has been collected from patients suffering from Alzheimer's disease, as well as from normal volunteers, activity other than normal walking. None of the subjects had received any prescription or investigational drugs for at a thorough investigation of the metabolism and elimination of this compound has not yet been conducted. The purpose least 1 month prior to entering the trial. There was no consumption of over-the-counter products, recreational of this study was to identify and characterize the primary routes of metabolism and elimination of donepezil HCl in drugs or alcohol from 72 h prior to admission until the end of the study. In addition, all subjects abstained from caffeinehumans, following the administration of a single 5 mg oral dose of 14 C-labelled donepezil. containing foods or beverages for the duration of the study.
Methods

Sample collection and analysis
Venous blood samples were collected prior to drug Subjects administration on day 1 (−1 h), and at 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216 and 240 h Eight healthy male subjects between 19 and 45 years of age participated in this study. Their body weights ranged from following drug administration. The samples were collected in three separate, heparinized, evacuated tubes for radio-60 to 85 kg and were within 20% of ideal weight for their height and body build based on the Metropolitan Insurance activity counting, analysis of donepezil plasma concentrations and metabolic profiling. Company Height and Weight Tables (1983) . None of the subjects had clinical evidence of significant gastrointestinal, Urine samples were collected continuously throughout the 10-day study period. On day 1, samples were collected renal, respiratory, endocrine, haematological, neurological, psychiatric or cardiovascular system abnormalities. Subjects in 4 h pooled aliquots, on day 2 samples were collected in 6 h pooled aliquots, and for the remaining 8 days, samples who had a known or suspected history of alcohol or drug misuse or a positive urine drug screen were excluded from were collected in 24 h pooled aliquots. Subjects were required to provide a baseline faecal sample entry, as were those who had donated blood within 1 month of entry, or who had participated in other radiolabelled drug at admission to the study site. During the study, faecal samples were pooled for each 24-h period. Samples were studies during the previous 12 months. Patients who were smokers or who were taking products containing nicotine collected in tarred, wide-mouth polypropylene-polyethylene jugs and frozen at −20°C following collection. Plasma were also excluded.
The study was conducted in accordance with the concentrations of donepezil HCl were measured using highperformance liquid chromatography (HPLC) with UV principles stated in the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board detection (315 nm) [3] . Concentrations were interpolated from calibration curves shown to be linear from 1 ng ml
for Investigations Involving Human Subjects, Harris Laboratories, Lincoln, Nebraska, USA. All subjects gave to 100 ng ml −1 . The lowest quantifiable concentration for the validated assay was 2 ng ml −1 . written informed consent prior to participation.
Pharmacokinetic analysis Protocol
This was an open-label, non-randomized study. Subjects
Characterization of donepezil and 14 C-donepezil pharmacokinetics was conducted using data from samples collected were admitted to the study site on the evening before drug administration. Baseline measurements (routine physical over a 144-h period following drug administration. Pharmacokinetic parameters were estimated using a nonexamination, weight and vital signs) were obtained upon admission. A urine drug screen was also performed, and compartmental model. The donepezil plasma concentration and total radioactivity data from each subject were plotted baseline urine and faecal samples were obtained. The following morning, after an 8-h fast, subjects received a as log concentration-time curves. Plasma radioactivity was expressed as ng donepezil equivalents per ml (ng single 5 mg (liquid) oral dose of donepezil. This dose was a 20 ml aqueous solution containing 4.6 mg of unlabelled equiv ml −1 ). The peak plasma concentration (C max ) and time to peak plasma concentration (t max ) were recorded donepezil and 0.4 mg (50 mCi) of 14 C-labelled donepezil (55 mCi mmol −1 , Amersham International, UK), followed from the observed values. The terminal disposition phase was identified by visual inspection of each subject's by 250 ml of tap water (three 30 ml washes of the glass vial plus 160 ml). This radiochemical form of donepezil was semi-logarithmic plot at points between 24 h and 144 h post-dose. The terminal disposition rate constant (l z ) was their body weights from 73.5 to 85.0 kg (mean 78.6 kg ), and their heights from 175 to 183 cm (mean 180.1 cm). estimated as −2.303 times the slope of the best-fit linear regression line of the terminal phase. The plasma half-life (t D ) was calculated as 0.693/l z . The area under the curve Metabolism and elimination (AUC) from 0 to 144 h (AUC ) was calculated by using the trapezoidal rule and extrapolated to infinity Plasma, urine and faecal samples for analysis were collected at specified intervals during the 10-day study period. Total (AUC (0-2 ) ), by adding the ratio of the last non-zero concentration occurring up to 144 h post-dose to l z .
recovery of radioactivity in subject samples averaged 72% of the administered dose (50 mCi). The average recovery in Clearance (CL T /F) was calculated as dose divided by the product of AUC (0-2 ) and F, a factor to account for urine was 57%, which was significantly greater than the average recovery in faeces (15%). Donepezil and donepezil bioavailability. The apparent volume of distribution ( V lz /F) was calculated as CL T /F divided by l z .
metabolite concentrations for the eight subjects over all time intervals are summarized in Table 1 .
Analysis of metabolites
Metabolite profile in plasma Characterization of 14 C-donepezil metabolism and eliminDue to the low levels of radioactivity recovered in plasma ation was based upon analysis of blood, urine and faecal samples (approximately 1500 dpm ml −1 ), it was necessary samples collected over the 10-day period following drug to pool samples collected from several time-points in order administration. Each collected sample was assayed for total to provide the necessary counts for metabolic profiling. radioactivity. Samples from specified time intervals for each Time-points were pooled to provide metabolite profiles matrix were used for metabolic profiling. Faecal samples during specific phases of the plasma concentration-time were homogenized in water (451 water5faeces). Urine, curve (absorption, C max , distribution and elimination) as faecal and plasma samples from specific time intervals were follows: 1, 2, 3 and 4 h; 6 and 8 h; 12, 18 and 24 h; 36, 48 pooled where indicated and stored frozen (−20°C) until and 72 h; 96-240 h. metabolite profile determination.
Plasma radioactivity concentrations peaked in the 6-8 h Total radioactive residue (TRR) in each pooled sample time interval at 10.09 ng equiv ml −1 . Donepezil, which was was determined for mass balance purposes. TRR in faecal found to be the principal component during all of the samples was determined by combustion to 14 CO 2 . TRR in plasma time intervals, accounted for 4.07 ng ml −1 during pooled urine samples was determined by liquid scintillation this interval. In general, donepezil accounted for about 25% counting (LSC). TRR in pooled plasma samples was of the recovered radioactivity in each time interval, with calculated from volumes and radioactivity concentrations the exception of the 6-8 h interval, where it accounted for determined on individual samples to conserve radioactivity about 40% of the total radioactive residue. for profiling. Pooled samples were extracted, hydrolysed
The recovered residue from plasma contained higher with b-glucuronidase (containing partial sulphatase activity) levels of the hydroxylated metabolites M1 and M2 than of and re-extracted, resulting in an aqueous phase, two organic their respective glucuronide (or sulphate) conjugates, M11 phases and a post-extraction solid phase (PES; faeces and M12. For example, the 4 h sample pool contained 0.65 and some plasma) for each sample. Both organic phases and 0.69 ng equiv ml −1 of M1 and M2, respectively, while were chromatographically analysed by one-dimensional M11 and M12 were present at concentrations of 0.33 and thin layer chromatography (1D-TLC). Extracts were co-0.38 ng equiv ml −1 , respectively. Of the metabolites found chromatographed and R f values (ratio to front value for in the initial 4 h sample pool, M6 was present in significant TLC) compared with authentic standards. Aqueous phases, quantities (1.53 ng equiv ml −1 ), although its concentration considered to contain polar materials, were assayed by LSC, steadily decreased in subsequent samples and was below but not analysed further.
detection limits (<0.05 ng equiv ml −1 ) in the 96-240 h pool. In contrast, the hydrolysis product M4 was not present in plasma in significant concentrations (≤0.1 ng equiv ml −1 ) Safety assessments for any time interval. All adverse events reported spontaneously by the subjects or As many as four unknown compounds were observed in observed during physical examination were documented, plasma, each of which was present at concentrations <0.9 ng together with times of onset and cessation, and assessment equiv ml −1 , on average, for all time intervals. The aqueous of severity and causality. Vital signs were monitored at phase, containing very polar residues, accounted for an regular intervals during the study. Laboratory evaluations average of 1.29 ng equiv ml −1 of radioactivity across all were conducted just prior to drug administration on day 1. time intervals. Mass balances accounted for an average of >70% of the total radioactive residue in each pooled sample.
Results
Metabolite profile in urine Subjects
Donepezil was the predominant compound excreted in urine by all subjects, over all time intervals. On average, it Eight healthy Caucasian male subjects were enrolled into the trial and all completed the 11-day monitoring period.
accounted for one-third of the total radioactive residue at each time interval. Therefore, of the total recovered dose in Their ages ranged from 19 to 43 years (mean 27 years), Table 1 Concentrations of donepezil and its metabolites found in plasma, and as a percentage of the total recovered dose in urine and faeces. The numbers shown are average values for all eight subjects over the 10-day collection period. urine (which was 57% of the administered dose), a 10). The most significant of the known metabolites in this matrix were the hydroxylation metabolites M1 and M2 cumulative total of 16.9% was donepezil. The aqueous phase accounted for approximately 14% of the recovered dose.
(0.66% and 0.59% of the recovered dose, respectively). On average, these two metabolites represented <0.4% of the The major metabolite present in urine was the hydrolysis product, M4, which accounted for approximately 6.1% of dose per time interval. The glucuronide (or sulphate) conjugates of these metabolites, M11 and M12, respectively, the dose.
The hydroxylation metabolites M1 and M2 were present were relatively insignificant and accounted for ≤0.1% of the dose for each time interval. The hydrolysis metabolite principally as their glucuronide (or sulphate) conjugates, M11 and M12, respectively. M11 and M12 accounted for M4 accounted for an average of 0.24% of the dose during the early phase, decreasing to 0.05% during the late phase. 4.9% and 2.1% of the dose, respectively, over the 10-day collection period, while M1 and M2 accounted for only
The N-oxidation product, M6, accounted for slightly lower levels (0.13% for the early phase, 0.02% for the late phase). 1.6% and 1.1% of the dose. The N-oxidation product M6 accounted for approximately 2% of the dose in urine As many as five unknown compounds were observed in the faeces, each averaging <0.2% of the dose for each time (Table 1) .
As many as six unknown compounds were observed in interval. A significant amount of radioactive residue was retained at or near the TLC origin, indicating unknown urine, each accounting for ≤2% of the dose, and accounting for no more than 4.5% of the dose collectively. Mass polar compounds unique to faeces (1.6% of recovered dose). These metabolites could not be identified. Additional balances accounted for an average of 93.5% of the total radioactive residue in each pooled sample. radioactivity was retained in the aqueous phase that also represented very polar residues (1.4% of the dose). These residues accounted for 0.76% of the dose during the early Metabolite profile in faeces phase and 0.27% of the dose during the late phase. Mass balances, including combustion of post-extraction solids, Faecal samples were collected throughout the 10-day study period, but were pooled because of variability in sample accounted for >70% of the total radioactive residue for each time interval. production between subjects and because of the low levels of radioactivity in each sample. Two-day intervals were chosen to examine the metabolic profile of donepezil during Pharmacokinetic data the early (days 2 and 3), middle (days 6 and 7) and late (days 9 and 10) phases of the sample collection period.
Mean plasma concentration-time curves for donepezil and 14 C-donepezil in plasma are shown in Figure 1 . The t max Approximately 15% of the administered dose was recovered in faeces during the 10-day period. The faecal values for donepezil and for 14 C-donepezil (total radioactivity) were very similar. The C max and AUC values, extracts contained proportionately less radioactive residue than the other matrices. The faecal matrix was the most however, were markedly higher for 14 C-donepezil than for donepezil, demonstrating the presence of both the parent difficult to extract of the three matrices, making chromatographic resolution and co-chromatographic resolution compound as well as donepezil metabolites (Table 2) . AUC (0-144) for 14 C-donepezil was 663.5±23.0 ng h ml −1 , difficult. Analysis of faecal samples was also hampered by large amounts of polar materials that did not migrate from 87% greater than for unlabelled donepezil (355.0±20.7 ng h ml −1 ). The AUC (0-2 ) for 14 C-donepezil was 897.3± the TLC origin and could not be identified.
Relatively little donepezil was measured in the faeces, 36.1 ng h ml −1 , 77% greater than for unlabelled donepezil (507.4±31.8 ng h ml −1 ). The ratio of donepezil AUC (0-144) although it represented the largest percentage of the known compounds identified during each of the three assessment to total 14 C-donepezil AUC (0-144) was 0.54. Donepezil was cleared from plasma faster than 14 Cintervals (1.1% of the recovered dose). On average, donepezil represented 0.75% of the dose during the early phase (days donepezil (clearance rates 0.129±0.009 and 0.072±0.003 l h −1 kg −1 , respectively). Donepezil also had an apparent 2 and 3), declining to 0.06% by the late phase (days 9 and with findings from animal studies showing biliary excretion to be the primary route of elimination (unpublished observations).
In total, 72% of the administered dose was recovered, with approximately 57% recovered in the urine and 15% in the faeces. These findings are in agreement with previous studies, which showed that approximately four times more radioactivity was found in the urine than in the faeces [1, 2] .
Although unchanged 14 C-donepezil was present in both urine and plasma throughout the 240-h collection period, the results presented here demonstrate that donepezil undergoes significant hepatic metabolism. Three metabolic pathways are proposed on the basis of the results presented: (i) O-dealkylation followed by hydroxylation to metabolites and (iii) N-oxidation to metabolite M6 (Figure 2 ). Additional metabolic pathways may be operative, as represented by the number of unknown compounds observed. However, as each unknown metabolite represented an average of <2% of the dose, these pathways are considered minor contributors to the metabolic process. Plasma levels of total radioactivity were significantly greater at the first blood sampling time-point following drug administration (1 h) than those of total donepezil (3.3 ng equiv ml −1 versus 1.6 ng ml −1 ), suggesting that first-pass hepatic metabolism plays an important role. However, in contrast to the pre-clinical studies, the primary metabolites observed in plasma were not the O-glucuronide conjugates, but instead the hydroxylation products M1 and M2 and the N-oxidation product M6. Total radioactivity levels in plasma remained consistently higher than total donepezil levels throughout the 10-day sampling period, volume of distribution, which was twice that calculated for suggesting that the metabolic products of donepezil have a 14 C-donepezil (Table 2) . t D similar to that of the parent compound. The consistent presence of metabolites throughout the plasma life span of Safety donepezil is demonstrated by markedly larger AUC values for total radioactivity, as well as the value of 0.54 for the Donepezil was well tolerated by all subjects, and there were donepezil AUC to total 14 C-donepezil AUC (0-144) no clinically significant changes in vital sign parameters ratio. during the course of the study. Four subjects reported mild In urine, the glucuronidated metabolites M11 and M12 headache during the study of which three reports were (glucuronidated products of M1 and M2, respectively) considered to be possibly related to donepezil. predominated, as did the hydrolysis product M4. All three of these metabolites were found in very low quantities in Discussion plasma, suggesting rapid elimination of these products following their formation. As in plasma, unchanged donepezil The results presented herein indicate that the primary route accounted for a large component of the recovered dose in for the elimination of donepezil and its metabolites in urine. The metabolites M1, M2 and M6, which were human subjects is renal rather than biliary. This contrasts Table 2 Comparison of pharmacokinetic parameters (mean±SE) for donepezil and predominant in plasma, were present only at very low levels and the hydrolysis product M4 are the primary pathways for elimination of donepezil. Faecal elimination of the hydroxylin this matrix.
Faecal extracts contained proportionally less radioactive ation products M1 and M2 and the N-oxidation product M6 appears to play a minor role. residue than the other matrices examined. Analysis of faecal samples was also hampered by large amounts of polar
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